Gabather Investor Relations Material
Latest events
Investor Update
Gabather
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Gabather
Access all reports
Gabather AB is a pharmaceutical company dedicated to developing therapeutics for central nervous system diseases. The company focuses on creating novel drug candidates primarily for the treatment of neuropsychiatric disorders, including anti-psychotics, anti-depressants, anxiolytics, analgesics, and cognition-enhancing treatments. The company is headquartered in Stockholm, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
GABA
Country
🇸🇪 Sweden